An Observational Study of Avastin (Bevacizumab) in First Line in Patients With Metastatic Colorectal Cancer (AVANiS)
This observational study will evaluate the use in clinical practice and the efficacy of Avastin (bevacizumab) in patients with metastatic colorectal cancer who have not received prior chemotherapy treatment in the metastatic setting. Patients for whom the treating physician has decided to initiate therapy with Avastin will be followed for 10 months.
Colorectal Cancer
Dosage/schedule of 1st-line Avastin, approximately 3 years|Duration of treatment, approximately 3 years|Chemotherapy regimens used in clinical practice, approximately 3 years|Clinical/demographic patient characteristics at baseline, approximately 3 years
Progression-free survival, approximately 3 years|Relationship between termination of Avastin treatment and time point of progression, approximately 3 years
This observational study will evaluate the use in clinical practice and the efficacy of Avastin (bevacizumab) in patients with metastatic colorectal cancer who have not received prior chemotherapy treatment in the metastatic setting. Patients for whom the treating physician has decided to initiate therapy with Avastin will be followed for 10 months.